Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.
Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
The National Cancer Institute awarded investigators at Huntsman Cancer Institute a grant totaling more than $3 million to conduct a clinical trial to see if combining creatine monohydrate supplementation and resistance exercise training helps preserve muscle in people who have metastatic prostate cancer.
Huntsman Cancer Institute at the University of Utah and Utah Valley University proudly announce a groundbreaking partnership called the “Huntsman Cancer Institute–Utah Valley University Health Collaborative.”
Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.
Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
The Center for Health Outcomes and Population Equity at Huntsman Cancer Institute and the University of Utah, in partnership with the Montana State University Center for American Indian and Rural Health Equity, received a grant for Cancer Control in Persistent Poverty Areas from the National Cancer Institute.
Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans today for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.
Huntsman Cancer Institute at the University of Utah, the only place in the region devoted to developing new treatments for cancer, announced the opening of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers.
Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.
Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.